Freeox Biotech is an innovative late-stage clinical company singularly focused on the discovery and development of Cerebrovascular Protective Therapeutics. A Phase III-ready investigational drug – Ox-01, the company’s lead asset – has been shown to be an effective emergency adjunct therapy to Mechanical Thrombectomy for the treatment of Acute Ischemic Stroke (AIS).